```json
{
"content": [
{
"type": "paragraph",
"content": "North America remains the dominant revenue contributor in the Fully Automated Chemiluminescent Immunoassay System market growth narrative, commanding an estimated 38% global share. The confluence of stringent CLIA quality mandates, a well-capilitated hospital network, and aggressive LabCorp-Quest reference-lab expansion keeps replacement cycles short and ASPs elevated. Regional forecast CAGR of 5.2% to 2028 is underpinned by CMS reimbursement clarity for high-sensitivity troponin and rising adoption of random-access platforms in mid-tier IDNs."
},
{
"type": "paragraph",
content: "Europe’s 27% slice is increasingly policy-driven: the IVDR 2022 transition is accelerating lab consolidation toward CE-marked closed systems, while Horizon Europe grants are co-financing AI-enhanced chemiluminescence readers. Asia Pacific is the fastest-growing region (8.4% CAGR) as China’s 14th Five-Year Plan channels US$1.3bn into county-level hospital automation, Japan’s ageing cohort >28% drives chronic-disease screening, and India’s production-linked incentive scheme slashes import dependence on reagents."
},
{
"type": "paragraph",
content: "Latin America (7% share) benefits from PAHO bulk-procurement tenders favoring 600-test/hour throughput systems, but forex volatility tempers premium upgrades. Middle East & Africa (4% share) is gaining traction via PPP dialysis chains in GCC states and World Bank health-systems strengthening loans that prioritize lab interoperability; however, skilled-staff shortages keep growth in the high-single digits, well below its theoretical demographic dividend."
}
],
"worldMapData": {
"regions": [
{ "name": "North America", "value": 38 },
{ "name": "Europe", "value": 27 },
{ "name": "Asia Pacific", "value": 24 },
{ "name": "Latin America", "value": 7 },
{ "name": "Middle East & Africa", "value": 4 }
]
}
}
```
